The historical rank and industry rank for Biofrontera AG's Pretax Margin % or its related term are showing as below:
LTS:0DOL'
s Pretax Margin % Range Over the Past 10 Years
Min: -172.58 Med: -28.56 Max: 123.96
Current: -7.01
LTS:0DOL's Pretax Margin % is ranked worse than 74.42% of 954
companies
in the Drug Manufacturers industry
Industry Median: 7.295
vs LTS:0DOL: -7.01
Biofrontera AG (LTS:0DOL) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Biofrontera AG Pretax Margin % Related Terms
Biofrontera AG Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Biofrontera AG's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DOL vs ZTS, UTHR, VTRS: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofrontera AG Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Biofrontera AG's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofrontera AG (LTS:0DOL) has a Pretax Margin % of 1.10% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Biofrontera AG and its competitors. According to the industry distribution chart, Biofrontera AG ranks #710 out of 954 companies in the Drug Manufacturers industry, placing it in the top 74.4%.
Is Biofrontera AG's Pretax Margin % too high?
Biofrontera AG's current Pretax Margin % is 1.10%. The Drug Manufacturers industry median Pretax Margin % is 7.30. Biofrontera AG's value of 1.10% is 84.9% below this industry median. Based on the distribution chart, Biofrontera AG ranks #710 out of 954 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Biofrontera AG has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Biofrontera AG's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofrontera AG ranks #710 out of 954 companies for Pretax Margin %. This places Biofrontera AG in the lower half of its industry. The industry median Pretax Margin % is 7.30. Biofrontera AG's value of 1.10% is 84.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofrontera AG's current Pretax Margin % of 1.10% is 84.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Biofrontera AG and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofrontera AG's current Pretax Margin % is 1.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera AG stock overvalued right now?
Biofrontera AG (LTS:0DOL) has a current Pretax Margin % of 1.10%. The stock's GF Value™ is €2.48, compared to a current price of €2.40 — trading 3.2% below its estimated fair value. The current Pretax Margin % is 1.10% and 84.9% below the Drug Manufacturers industry median of 7.30. Biofrontera AG's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Biofrontera AG (LTS:0DOL), the current Pretax Margin % is 1.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofrontera AG (LTS:0DOL) Overvalued in 2026?
Based on GuruFocus' analysis, Biofrontera AG stock appears to be undervalued.
The current stock price of €2.40 is trading 3.2% below its estimated GF Value™ of €2.48.
Key valuation signals for LTS:0DOL:
Pretax Margin %: 1.10%
GF Value™: €2.48 vs. price of €2.40 (3.2% below fair value)
Industry Position: 84.9% below the Drug Manufacturers median (#710 of 954)
No single metric tells the full story. See the LTS:0DOL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
58GF Score
Get the complete analysis for LTS:0DOL
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DOL has been successfully added to your 
